NCT05207423

A Chart Review Study of Adults With Advanced NSCLC

Patterns of Care and Clinical Outcomes of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 179 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main aim is to see how treatment patterns and drugs might improve care for adults with advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon-20 driven mutations. Past medical records will be reviewed. No clinic visits or procedures will be required.

Detailed description

This is a retrospective, observational study in participants with advanced NSCLC with EGFR exon-20 driven mutations. This study will look at clinical outcomes, patterns of care and disease management strategies and healthcare resource utilization (HCRU) in a routine clinical practice setting in the real world. The study will enroll approximately 218 participants. Participants who were treated at the participating sites between 01 January 2017 and 30 November 2021 will be included. The data will be collected retrospectively at the specialized centers from the participants medical records and notes. All the participants will be assigned to a single observational cohort: • Participants With Advanced NSCLC With EGFR Exon-20 Mutations This multi-center study will be conducted in Canada, France and Hong Kong. The overall duration of the study will be 6 months.

Conditions

• Non-small Cell Lung Cancer (NSCLC)

Timeline

• Start date: 2022-10-03
• Primary completion: 2023-02-13
• Completion: 2023-02-13
• First posted: 2022-01-26
• Last updated: 2023-02-28

Locations

30 sites across 3 countries: Canada, France, Hong Kong